DB:PHH2

Stock Analysis Report

Executive Summary

Paul Hartmann AG manufactures and sells medical and hygiene products for wound care, incontinence, disinfection, and surgical efficiency in Europe, North and South America, Africa, Asia, and Oceania.


Snowflake Analysis

Flawless balance sheet average dividend payer.


Similar Companies

Share Price & News

How has Paul Hartmann's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PHH2 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

PHH2

-2.7%

DE Medical Equipment

-4.7%

DE Market


1 Year Return

-5.8%

PHH2

21.2%

DE Medical Equipment

8.3%

DE Market

Return vs Industry: PHH2 underperformed the German Medical Equipment industry which returned 21.2% over the past year.

Return vs Market: PHH2 underperformed the German Market which returned 8.3% over the past year.


Shareholder returns

PHH2IndustryMarket
7 Day0%-2.7%-4.7%
30 Day2.1%-9.2%-4.0%
90 Day-2.0%-4.5%-1.4%
1 Year-3.7%-5.8%23.1%21.2%11.7%8.3%
3 Year-25.8%-30.0%129.0%123.1%11.4%1.6%
5 Year-6.2%-14.5%258.5%240.7%15.1%-0.7%

Price Volatility Vs. Market

How volatile is Paul Hartmann's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Paul Hartmann undervalued compared to its fair value and its price relative to the market?

13.98x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: PHH2 (€290) is trading above our estimate of fair value (€201.15)

Significantly Below Fair Value: PHH2 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PHH2 is good value based on its PE Ratio (14x) compared to the Medical Equipment industry average (37.8x).

PE vs Market: PHH2 is good value based on its PE Ratio (14x) compared to the German market (20.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PHH2's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PHH2 is good value based on its PB Ratio (1.2x) compared to the DE Medical Equipment industry average (5.8x).


Next Steps

Future Growth

How is Paul Hartmann forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Paul Hartmann has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Paul Hartmann performed over the past 5 years?

2.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PHH2 has high quality earnings.

Growing Profit Margin: PHH2's current net profit margins (3.4%) are lower than last year (4%).


Past Earnings Growth Analysis

Earnings Trend: PHH2's earnings have grown by 2.7% per year over the past 5 years.

Accelerating Growth: PHH2's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PHH2 had negative earnings growth (-12.8%) over the past year, making it difficult to compare to the Medical Equipment industry average (17%).


Return on Equity

High ROE: PHH2's Return on Equity (8.7%) is considered low.


Next Steps

Financial Health

How is Paul Hartmann's financial position?


Financial Position Analysis

Short Term Liabilities: PHH2's short term assets (€867.6M) exceed its short term liabilities (€400.7M).

Long Term Liabilities: PHH2's short term assets (€867.6M) exceed its long term liabilities (€301.6M).


Debt to Equity History and Analysis

Debt Level: PHH2's debt to equity ratio (11.9%) is considered satisfactory.

Reducing Debt: PHH2's debt to equity ratio has reduced from 21.6% to 11.9% over the past 5 years.

Debt Coverage: PHH2's debt is well covered by operating cash flow (130.2%).

Interest Coverage: PHH2's interest payments on its debt are well covered by EBIT (68x coverage).


Balance Sheet

Inventory Level: PHH2 has a high level of physical assets or inventory.

Debt Coverage by Assets: PHH2's debt is covered by short term assets (assets are 8.1x debt).


Next Steps

Dividend

What is Paul Hartmann's current dividend yield, its reliability and sustainability?

2.41%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: PHH2's dividend (2.41%) is higher than the bottom 25% of dividend payers in the German market (1.38%).

High Dividend: PHH2's dividend (2.41%) is low compared to the top 25% of dividend payers in the German market (3.73%).


Stability and Growth of Payments

Stable Dividend: PHH2's dividends per share have been stable in the past 10 years.

Growing Dividend: PHH2's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (33.7%), PHH2's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.4yrs

Average management tenure


CEO

Britta Fuenfstueck 0

1.1yrs

Tenure

Ms. Britta Fuenfstueck has been Chief Executive Officer at Paul Hartmann AG since January 1, 2019 and its Management Board since January 1, 2019. Ms. Fuenfstueck served as Chairman of the Management Board  ...


Leadership Team

NamePositionTenureCompensationOwnership
Britta Fuenfstueck
CEO & Member of Management Board1.1yrsno datano data
Michel Kuehn
Chief Hygiene Officer & Member of Management Board11.3yrsno datano data
Raymund Heinen
Chief Process Officer & Member of the Management Board4.3yrsno datano data
François Georgelin
Member of the Management Board0.08yrsno datano data
Michael Banz
Vice President of Corporate Legal0yrsno datano data
Gabriele Müller
Vice President of Human Resources Management9.1yrsno datano data
Ralf Fenske
Senior Vice President of Corporate Accounting0yrsno datano data
Peter Halbauer
Head of Group Purchasing Management12.1yrsno datano data
Michael Brauner
Executive Managing Director of SANIMED Group Germany6.4yrsno datano data
Christian Sievert
Senior Vice President Business Unit Risk Prevention0yrsno datano data

6.4yrs

Average Tenure

Experienced Management: PHH2's management team is seasoned and experienced (6.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Wolfgang Röhrl
Vice President Operations Management Medical Production & Member of Supervisory Board2.1yrsno datano data
Joachim Schielke
Member of Supervisory Board11.8yrs€22.50kno data
Fritz-Jürgen Heckmann
Chairman of Supervisory Board14.6yrs€69.50kno data
Werner Casper
Member of Supervisory Board0yrs€22.50kno data
Eduard Schleicher
Member of Supervisory Board11.8yrs€53.83kno data
Gerhard Hirth
Member of Supervisory Board11.8yrs€22.50kno data
Rinaldo Riguzzi
Member of Supervisory Board6.6yrsno datano data
Christine Geppert
Member of Supervisory Board0yrs€22.50kno data
Ralf Willeck
Deputy Chairman of the Supervisory Board 0yrsno datano data
Yvonne Brix
Member of Supervisory Board6.8yrsno datano data

11.8yrs

Average Tenure

Experienced Board: PHH2's board of directors are seasoned and experienced ( 11.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Paul Hartmann AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Paul Hartmann AG
  • Ticker: PHH2
  • Exchange: DB
  • Founded: 1818
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: €1.016b
  • Shares outstanding: 3.55m
  • Website: https://hartmann.info

Number of Employees


Location

  • Paul Hartmann AG
  • Paul-Hartmann-Strasse 12
  • Heidenheim
  • Baden-Württemberg
  • 89522
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHH2DB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1992
PLHN.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 1992

Biography

Paul Hartmann AG manufactures and sells medical and hygiene products for wound care, incontinence, disinfection, and surgical efficiency in Europe, North and South America, Africa, Asia, and Oceania. The company offers disinfectant products for hands, surface, and instruments; cleaning, skin care, and skin antisepsis products, as well as Sterillium, a hand disinfectant; incontinence management products; and personal healthcare products, such as diagnostic devices and first aid products. It also provides single-use and pre-surgical products, disposable surgical gloves, clothing and gowns, and disposable drapes for use in operating theatres, treatment rooms, and wards; and wound management solutions, including traditional compresses, bandages, hydro therapy products. The company offers its products and services to nursing and healthcare professionals, home residents, and patients. Paul Hartmann AG was founded in 1818 and is based in Heidenheim, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 20:58
End of Day Share Price2020/02/24 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.